Genmab A/S (NASDAQ:GMAB) Stock Rating Lowered by Wall Street Zen

Genmab A/S (NASDAQ:GMAB) was downgraded by equities research analysts at Wall Street Zen from a “buy” rating to a “hold” rating in a research note issued to investors on Saturday.

Several other research analysts also recently weighed in on GMAB. Sanford C. Bernstein downgraded Genmab A/S from a “market perform” rating to an “underperform” rating in a research note on Tuesday, April 1st. HC Wainwright reiterated a “buy” rating and issued a $37.00 target price (down from $50.00) on shares of Genmab A/S in a research note on Wednesday, April 9th. William Blair upgraded Genmab A/S from a “market perform” rating to an “outperform” rating in a research note on Tuesday, March 11th. Finally, Truist Financial lowered their target price on Genmab A/S from $50.00 to $45.00 and set a “buy” rating on the stock in a research note on Tuesday, March 11th. One equities research analyst has rated the stock with a sell rating, four have assigned a hold rating, eight have issued a buy rating and one has issued a strong buy rating to the company. According to data from MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and an average target price of $39.17.

Genmab A/S Stock Down 1.2%

NASDAQ:GMAB opened at $22.82 on Friday. The stock’s 50 day moving average price is $20.56 and its 200 day moving average price is $20.74. The company has a market capitalization of $14.63 billion, a PE ratio of 13.11, a P/E/G ratio of 2.65 and a beta of 0.96. Genmab A/S has a 52-week low of $17.24 and a 52-week high of $28.56.

Genmab A/S (NASDAQ:GMAB) last released its quarterly earnings results on Thursday, May 8th. The company reported $0.31 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.23 by $0.08. The firm had revenue of $715.00 million for the quarter, compared to the consensus estimate of $5.17 billion. Genmab A/S had a return on equity of 16.78% and a net margin of 36.30%. As a group, sell-side analysts anticipate that Genmab A/S will post 1.45 EPS for the current fiscal year.

Institutional Investors Weigh In On Genmab A/S

Institutional investors have recently added to or reduced their stakes in the company. Raymond James Financial Inc. purchased a new stake in Genmab A/S during the fourth quarter valued at about $2,463,000. AIMZ Investment Advisors LLC acquired a new position in shares of Genmab A/S during the fourth quarter worth about $3,525,000. Northern Trust Corp lifted its stake in shares of Genmab A/S by 18.8% during the fourth quarter. Northern Trust Corp now owns 599,381 shares of the company’s stock worth $12,509,000 after purchasing an additional 94,858 shares in the last quarter. Sei Investments Co. lifted its stake in shares of Genmab A/S by 55.2% during the fourth quarter. Sei Investments Co. now owns 57,702 shares of the company’s stock worth $1,205,000 after purchasing an additional 20,525 shares in the last quarter. Finally, LPL Financial LLC lifted its stake in shares of Genmab A/S by 3.3% during the fourth quarter. LPL Financial LLC now owns 195,436 shares of the company’s stock worth $4,079,000 after purchasing an additional 6,288 shares in the last quarter. Hedge funds and other institutional investors own 7.07% of the company’s stock.

About Genmab A/S

Genmab A/S develops antibody therapeutics for the treatment of cancer and other diseases primarily in Denmark. The company markets DARZALEX, a human monoclonal antibody for the treatment of patients with multiple myeloma (MM); teprotumumab for the treatment of thyroid eye disease; and Amivantamab for advanced or metastatic gastric or esophageal cancer and NSCLC.